首页 > 最新文献

肿瘤研究与临床最新文献

英文 中文
Value of shear wave elastography in the differential diagnosis of breast small nodules 横波弹性成像在乳腺小结节鉴别诊断中的价值
Q4 Medicine Pub Date : 2020-02-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.013
Jie Liu, Jian-Ming Ma
目的 探讨剪切波弹性成像(SWE)对乳腺小结节的鉴别诊断价值。 方法 选取2018年6月到2019年1月山西省儿童医院及山西医科大学第二医院经手术病理证实的女性乳腺小结节(结节最大径≤10 mm)患者77例,共101个结节(良性35个,恶性66个),术前均行常规二维超声及SWE检查。以术后病理结果为金标准,比较良、恶性小结节的弹性模量值[最大值(Emax)、平均值(Emean)、最小值(Emin)],并绘制受试者工作特征曲线(ROC),得到Emax、Emean、Emin的最佳诊断界值及三者诊断乳腺恶性小结节的准确度。以准确性高的弹性模量值作为SWE诊断乳腺恶性小结节的标准,以美国放射学会建立的乳腺影像报告和数据系统(BI-RADS)分级作为常规二维超声诊断乳腺恶性小结节的标准,分别计算出SWE、BI-RADS诊断的灵敏度、特异度、准确度、阴性预测值及阳性预测值。 结果 乳腺恶性小结节的Emax、Emean、Emin均大于良性小结节,差异均有统计学意义(均P<0.01)。Emax、Emean、Emin诊断乳腺恶性小结节的最佳诊断界值分别为40.5、35.5、20.5 kPa,曲线下面积分别为0.986、0.980、0.746。以Emax≥40.5 kPa作为诊断乳腺恶性小结节标准的灵敏度、特异度、准确度、阴性预测值、阳性预测值分别为93.7%、90.2%、92.1%、88.6%、79.5%,以Emean≥35.5 kPa作为标准时分别为92.4%、94.3%、93.1%、96.8%、86.8%,均高于BI-RADS的70.8%、74.2%、71.4%、62.8%、46.3%;以Emin≥20.5 kPa作为标准时的灵敏度、特异度、约登指数分别为56.8%、98.2%、55.0%。 结论 相对于常规二维超声,SWE对乳腺恶性小结节具有较高的诊断价值。
目的 探讨剪切波弹性成像(SWE)对乳腺小结节的鉴别诊断价值。 方法 选取2018年6月到2019年1月山西省儿童医院及山西医科大学第二医院经手术病理证实的女性乳腺小结节(结节最大径≤10 mm)患者77例,共101个结节(良性35个,恶性66个),术前均行常规二维超声及SWE检查。以术后病理结果为金标准,比较良、恶性小结节的弹性模量值[最大值(Emax)、平均值(Emean)、最小值(Emin)],并绘制受试者工作特征曲线(ROC),得到Emax、Emean、Emin的最佳诊断界值及三者诊断乳腺恶性小结节的准确度。以准确性高的弹性模量值作为SWE诊断乳腺恶性小结节的标准,以美国放射学会建立的乳腺影像报告和数据系统(BI-RADS)分级作为常规二维超声诊断乳腺恶性小结节的标准,分别计算出SWE、BI-RADS诊断的灵敏度、特异度、准确度、阴性预测值及阳性预测值。 结果 乳腺恶性小结节的Emax、Emean、Emin均大于良性小结节,差异均有统计学意义(均P<0.01)。Emax、Emean、Emin诊断乳腺恶性小结节的最佳诊断界值分别为40.5、35.5、20.5 kPa,曲线下面积分别为0.986、0.980、0.746。以Emax≥40.5 kPa作为诊断乳腺恶性小结节标准的灵敏度、特异度、准确度、阴性预测值、阳性预测值分别为93.7%、90.2%、92.1%、88.6%、79.5%,以Emean≥35.5 kPa作为标准时分别为92.4%、94.3%、93.1%、96.8%、86.8%,均高于BI-RADS的70.8%、74.2%、71.4%、62.8%、46.3%;以Emin≥20.5 kPa作为标准时的灵敏度、特异度、约登指数分别为56.8%、98.2%、55.0%。 结论 相对于常规二维超声,SWE对乳腺恶性小结节具有较高的诊断价值。
{"title":"Value of shear wave elastography in the differential diagnosis of breast small nodules","authors":"Jie Liu, Jian-Ming Ma","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.013","url":null,"abstract":"目的 \u0000探讨剪切波弹性成像(SWE)对乳腺小结节的鉴别诊断价值。 \u0000 \u0000 \u0000方法 \u0000选取2018年6月到2019年1月山西省儿童医院及山西医科大学第二医院经手术病理证实的女性乳腺小结节(结节最大径≤10 mm)患者77例,共101个结节(良性35个,恶性66个),术前均行常规二维超声及SWE检查。以术后病理结果为金标准,比较良、恶性小结节的弹性模量值[最大值(Emax)、平均值(Emean)、最小值(Emin)],并绘制受试者工作特征曲线(ROC),得到Emax、Emean、Emin的最佳诊断界值及三者诊断乳腺恶性小结节的准确度。以准确性高的弹性模量值作为SWE诊断乳腺恶性小结节的标准,以美国放射学会建立的乳腺影像报告和数据系统(BI-RADS)分级作为常规二维超声诊断乳腺恶性小结节的标准,分别计算出SWE、BI-RADS诊断的灵敏度、特异度、准确度、阴性预测值及阳性预测值。 \u0000 \u0000 \u0000结果 \u0000乳腺恶性小结节的Emax、Emean、Emin均大于良性小结节,差异均有统计学意义(均P<0.01)。Emax、Emean、Emin诊断乳腺恶性小结节的最佳诊断界值分别为40.5、35.5、20.5 kPa,曲线下面积分别为0.986、0.980、0.746。以Emax≥40.5 kPa作为诊断乳腺恶性小结节标准的灵敏度、特异度、准确度、阴性预测值、阳性预测值分别为93.7%、90.2%、92.1%、88.6%、79.5%,以Emean≥35.5 kPa作为标准时分别为92.4%、94.3%、93.1%、96.8%、86.8%,均高于BI-RADS的70.8%、74.2%、71.4%、62.8%、46.3%;以Emin≥20.5 kPa作为标准时的灵敏度、特异度、约登指数分别为56.8%、98.2%、55.0%。 \u0000 \u0000 \u0000结论 \u0000相对于常规二维超声,SWE对乳腺恶性小结节具有较高的诊断价值。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47834298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide specifically binding to human medullary breast carcinoma Bcap-37 cells selected by phage display in vivo and its property as well as combination effect 噬菌体筛选的人髓质乳腺癌Bcap-37细胞特异性结合肽的体内展示及其性质及联合效应
Q4 Medicine Pub Date : 2020-02-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.002
C. Guo, Qi Zuo, Xiaofeng Yang, Fan Zhang
Objective To investigate the property and the combination effect of the peptide specifically binding to human medullary breast cancer Bcap-37 cells by using phage display in vivo and to provide molecular targeting probe for early diagnosis of breast cancer. Methods The human medullary breast carcinoma Bcap-37 cells tumor-bearing nude mice model was prepared and three rounds in vivo were performed by using Ph.D.-C7CTM phage display peptide library. The distribution of screened phages in tumors and normal tissues was detected by using immunohistochemistry. The affinity of monoclonal phage to Bcap-37 cells was identified by using enzyme linked immunosorbent assay (ELISA). The positive monoclonal phage DNA was taken and sequenced, and the sequence with high repetition rate was selected to synthesize peptide by using chemical methods. Optical molecular probe was prepared and fluorescence molecular imaging was used to test its specificity and targeting ability for breast transplantation tumor of tumor-bearing nude mice in vivo. Results The recovery rate of phage in the third round screening in vivo was 107.2 times than that in the first round. Immunohistochemical results showed that the phages binding to the tumor tissues were increased successively with the increasing screening rounds in vivo. The number of phages binding to tumor tissues was more than that binding to normal tissues (lung, skeletal muscle, liver and kidney). The absorbancy (A) value of section scanning image in the tumor tissues was higher than that in the normal tissues, and the difference was statistically significant different (P < 0.05). ELISA results showed that 22 phages (affinity≥2) among the 50 randomly selected monoclonal phage were positive. After DNA sequencing analysis of the positive monoclonal phage, 4 repeat amino acid sequences were obtained. The fluorescein isothiocyanate-labelled (FITC)-CSPLNTRFC with the highest repetition rate was synthesized for FITC-CSPLNTRFC peptide. Bcap-37 cells tumor-bearing nude mice model assay in vivo showed that FITC-CSPLNTRFC peptide could significantly enriched in the breast xenograft tissues. Conclusion CSPLNTRFC peptide specifically binding to human medullary breast cancer Bcap-37 cells can be screened out successfully by using phage display in vivo, which will be helpful to vitro studies on the early diagnosis of breast cancer. Key words: Breast neoplasms; Peptide library; Phage display; Specifically binding peptide
目的应用噬菌体展示技术研究肽与人癌症髓样细胞Bcap-37特异性结合的特性及其联合作用,为癌症的早期诊断提供分子靶向探针。方法制备人乳腺髓样癌Bcap-37细胞荷瘤裸鼠模型,利用Ph.D.C7CTM噬菌体展示肽库进行体内三轮实验。应用免疫组织化学方法检测筛选出的噬菌体在肿瘤和正常组织中的分布。单克隆噬菌体对Bcap-37细胞的亲和力通过酶联免疫吸附试验(ELISA)进行鉴定。对阳性的单克隆噬菌体DNA进行测序,选择重复率高的序列,用化学方法合成肽。制备了光学分子探针,并用荧光分子成像技术在体内检测其对荷瘤裸鼠乳腺移植瘤的特异性和靶向能力。结果第三轮体内筛选的噬菌体回收率是第一轮的107.2倍。免疫组化结果显示,随着体内筛选次数的增加,与肿瘤组织结合的噬菌体数量依次增加。与肿瘤组织结合的噬菌体数量多于与正常组织(肺、骨骼肌、肝和肾)结合的噬菌体。切片扫描图像在肿瘤组织中的吸光度(A)值高于正常组织,差异有统计学意义(P<0.05)。ELISA结果显示,在随机选择的50个单克隆噬菌体中,有22个噬菌体(亲和力≥2)呈阳性。对阳性单克隆噬菌体进行DNA测序分析,得到4个重复氨基酸序列。合成了重复率最高的异硫氰酸荧光素标记(FITC)-CPLNTRFC肽。Bcap-37细胞荷瘤裸鼠体内模型试验表明,FITC-CSPLNTRFC肽可在乳腺异种移植物组织中显著富集。结论应用噬菌体展示技术可在体内成功筛选出与人癌症髓样细胞Bcap-37特异性结合的CSPLNTRFC肽,这将有助于体外研究癌症的早期诊断。关键词:乳腺肿瘤;肽库;噬菌体展示;特异性结合肽
{"title":"Peptide specifically binding to human medullary breast carcinoma Bcap-37 cells selected by phage display in vivo and its property as well as combination effect","authors":"C. Guo, Qi Zuo, Xiaofeng Yang, Fan Zhang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.002","url":null,"abstract":"Objective \u0000To investigate the property and the combination effect of the peptide specifically binding to human medullary breast cancer Bcap-37 cells by using phage display in vivo and to provide molecular targeting probe for early diagnosis of breast cancer. \u0000 \u0000 \u0000Methods \u0000The human medullary breast carcinoma Bcap-37 cells tumor-bearing nude mice model was prepared and three rounds in vivo were performed by using Ph.D.-C7CTM phage display peptide library. The distribution of screened phages in tumors and normal tissues was detected by using immunohistochemistry. The affinity of monoclonal phage to Bcap-37 cells was identified by using enzyme linked immunosorbent assay (ELISA). The positive monoclonal phage DNA was taken and sequenced, and the sequence with high repetition rate was selected to synthesize peptide by using chemical methods. Optical molecular probe was prepared and fluorescence molecular imaging was used to test its specificity and targeting ability for breast transplantation tumor of tumor-bearing nude mice in vivo. \u0000 \u0000 \u0000Results \u0000The recovery rate of phage in the third round screening in vivo was 107.2 times than that in the first round. Immunohistochemical results showed that the phages binding to the tumor tissues were increased successively with the increasing screening rounds in vivo. The number of phages binding to tumor tissues was more than that binding to normal tissues (lung, skeletal muscle, liver and kidney). The absorbancy (A) value of section scanning image in the tumor tissues was higher than that in the normal tissues, and the difference was statistically significant different (P < 0.05). ELISA results showed that 22 phages (affinity≥2) among the 50 randomly selected monoclonal phage were positive. After DNA sequencing analysis of the positive monoclonal phage, 4 repeat amino acid sequences were obtained. The fluorescein isothiocyanate-labelled (FITC)-CSPLNTRFC with the highest repetition rate was synthesized for FITC-CSPLNTRFC peptide. Bcap-37 cells tumor-bearing nude mice model assay in vivo showed that FITC-CSPLNTRFC peptide could significantly enriched in the breast xenograft tissues. \u0000 \u0000 \u0000Conclusion \u0000CSPLNTRFC peptide specifically binding to human medullary breast cancer Bcap-37 cells can be screened out successfully by using phage display in vivo, which will be helpful to vitro studies on the early diagnosis of breast cancer. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Peptide library; Phage display; Specifically binding peptide","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44414053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of myelosuppression in the chemotherapy of early breast cancer 骨髓抑制在早期乳腺癌化疗中的意义
Q4 Medicine Pub Date : 2020-02-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.016
Ying Chen, Yifan Zhang, Jinxiang Zhang, Jiaqi Wang
Chemotherapy has become an important therapy for breast cancer. The myelosuppression is an inevitable adverse reaction during the chemotherapy, as well as a sign of drug effectiveness to some degree. Some retrospective studies have found that the patients with myelosuppression show the better survival in the chemotherapy of early breast cancer. This paper discusses the significance of myelosuppression in the chemotherapy of early breast cancer. Key words: Breast neoplasms; Neutropenia; Drug therapy, combination; Myelosuppression
化疗已成为癌症的重要治疗手段。骨髓抑制是化疗过程中不可避免的不良反应,也是某种程度上药物有效性的标志。一些回顾性研究发现,骨髓抑制患者在癌症早期化疗中表现出更好的生存率。本文探讨骨髓抑制在癌症早期化疗中的意义。关键词:乳腺肿瘤;中性粒细胞减少症;药物治疗,联合用药;骨髓抑制
{"title":"Significance of myelosuppression in the chemotherapy of early breast cancer","authors":"Ying Chen, Yifan Zhang, Jinxiang Zhang, Jiaqi Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.016","url":null,"abstract":"Chemotherapy has become an important therapy for breast cancer. The myelosuppression is an inevitable adverse reaction during the chemotherapy, as well as a sign of drug effectiveness to some degree. Some retrospective studies have found that the patients with myelosuppression show the better survival in the chemotherapy of early breast cancer. This paper discusses the significance of myelosuppression in the chemotherapy of early breast cancer. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Neutropenia; Drug therapy, combination; Myelosuppression","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43612186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on the mechanism of inhibiting invasion of human laryngeal squamous cell carcinoma Hep-2 and TU212 cells after the downregulation of miRNA-106b 下调miRNA-106b后抑制人喉癌Hep-2和TU212细胞侵袭的机制研究
Q4 Medicine Pub Date : 2020-02-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.003
Ke-min Cai, Qingxiao Guo, Fei Wang, Bo Yang
Objective To investigate the effect of miRNA-106b (miR-106b) on human laryngeal squamous cell carcinoma Hep-2 and TU212 cells and its mechanism. Methods Hep-2 and TU212 cells were divided into miR-106b inhibitory sequence transfected group (the experimental group), miR-106b competitive negative sequence transfected group (the negative control group) and non-intervention group (the blank group). The inhibitory effect of miR-106b inhibitory sequence on the expression of miR-106b was verified by using reverse transcription quantitative polymerase chain reaction (qRT-PCR). Whether phosphatase and tensin homolog (PTEN) was the target gene of miR-106b was analyzed by using bioinformatics and luciferase report vector. PTEN small interfering RNA (siRNA) was used to inhibit the expression of PTEN in Hep-2 and TU212 cells. Transwell method and Western blot were used to detect the change of invasion ability of Hep-2 and TU212 cells after miR-106b silencing or the PTEN intervening, and the expression change of PTEN, epithelial cadherin and vimentin. Results The relative expression levels of miR-106b in Hep-2 and TU212 cells in the experimental group were 0.110 ± 0.037 and 0.074 ± 0.009, respectively, which were lower than those in the negative control group (1.013±0.059 and 1.035±0.062, respectively; all P < 0.05). In Transwell experiments, the number of invasive cells in each field of Hep-2 and TU212 cells in the experimental group was less than that in the negative control group [(37.09±4.02) vs. (95.65±4.77), (29.16±2.49) vs. (103.19±6.08), all P < 0.05]. The bioinformatics analysis results showed that 3'-UTR region of PTEN mRNA was complementary to 3'-UTR region of miR-106b. Dual-luciferase reporter system analysis showed that the luciferase reporter activity of wild-type PTEN gene transfected with miR-106b was decreased to (22.84±2.68)%, and that of mutant PTEN gene transfected with miR-106b was almost unchanged [(92.08±3.44)%], and the difference was statistically significant (P < 0.001). The expression level of PTEN protein of Hep-2 and TU212 cells in the experimental group was higher than that in the negative control group. Transwell method showed that the number of invasive cells in each field of Hep-2 and TU212 cells in the experimental group with the inhibition of PTEN expression was more than that in the experimental group without the inhibition of PTEN expression [(65.08±3.57) vs. (26.72±2.58), (57.38±4.96) vs. (31.81±2.97), all P < 0.05]. Western blot showed that the expression level of epithelial-cadherin was up-regulated and vimentin was down-regulated of Hep-2 and TU212 cells in the experimental group with the inhibition of PTEN expression. Conclusions The human laryngeal squamous cell carcinoma Hep-2 and TU212 cell miR-106b can influence the downstream invasion-related protein of PTEN and change the cell invasion ability through the targeted regulation of PTEN expression. Key words: Laryngeal neoplasms; Carcinoma, s
目的探讨miRNA-106b(miR-106b)对人喉鳞状细胞癌Hep-2和TU212细胞的作用及其机制。方法将Hep-2和TU212细胞分为miR-106b抑制性序列转染组(实验组)、miR-106b竞争性负序转染组(阴性对照组)和非干预组(空白组)。通过逆转录定量聚合酶链反应(qRT-PCR)验证了miR-106b抑制序列对miR-106b表达的抑制作用。利用生物信息学和荧光素酶报告载体分析了miR-106b的靶基因是否为磷酸酶和紧张素同源物(PTEN)。PTEN小干扰RNA(siRNA)用于抑制PTEN在Hep-2和TU212细胞中的表达。采用Transwell法和Western印迹法检测miR-106b沉默或PTEN干预后Hep-2和TU212细胞侵袭能力的变化,以及PTEN、上皮钙粘蛋白和波形蛋白的表达变化。结果实验组Hep-2和TU212细胞中miR-106b的相对表达水平分别为0.110±0.037和0.074±0.009,低于阴性对照组(分别为1.013±0.059和1.035±0.062;均P<0.05),实验组Hep-2和TU212细胞各领域的侵袭细胞数均少于阴性对照组[(37.09±4.02)vs.(95.65±4.77),(29.16±2.49)vs。双荧光素酶报告子系统分析显示,转染miR-106b的野生型PTEN基因的荧光素素酶报告子活性降至(22.84±2.68)%,而转染miR-106b的突变型PTEN几乎没有变化[(92.08±3.44)%],实验组Hep-2和TU212细胞PTEN蛋白的表达水平高于阴性对照组。Transwell法显示,抑制PTEN表达的实验组Hep-2和TU212细胞各领域的侵袭细胞数均高于未抑制PTEN的实验组[(65.08±3.57)vs.(26.72±2.58),(57.38±4.96)vs在抑制PTEN表达的情况下,实验组Hep-2和TU212细胞的波形蛋白上调和下调。结论人喉鳞状细胞癌Hep-2和TU212细胞miR-106b可通过靶向调节PTEN的表达,影响PTEN下游侵袭相关蛋白,改变细胞侵袭能力。关键词:喉肿瘤;癌,鳞状细胞;肿瘤侵袭性;RNA干扰;miRNA-106b;磷酸酶和紧张素同源物
{"title":"Study on the mechanism of inhibiting invasion of human laryngeal squamous cell carcinoma Hep-2 and TU212 cells after the downregulation of miRNA-106b","authors":"Ke-min Cai, Qingxiao Guo, Fei Wang, Bo Yang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.003","url":null,"abstract":"Objective \u0000To investigate the effect of miRNA-106b (miR-106b) on human laryngeal squamous cell carcinoma Hep-2 and TU212 cells and its mechanism. \u0000 \u0000 \u0000Methods \u0000Hep-2 and TU212 cells were divided into miR-106b inhibitory sequence transfected group (the experimental group), miR-106b competitive negative sequence transfected group (the negative control group) and non-intervention group (the blank group). The inhibitory effect of miR-106b inhibitory sequence on the expression of miR-106b was verified by using reverse transcription quantitative polymerase chain reaction (qRT-PCR). Whether phosphatase and tensin homolog (PTEN) was the target gene of miR-106b was analyzed by using bioinformatics and luciferase report vector. PTEN small interfering RNA (siRNA) was used to inhibit the expression of PTEN in Hep-2 and TU212 cells. Transwell method and Western blot were used to detect the change of invasion ability of Hep-2 and TU212 cells after miR-106b silencing or the PTEN intervening, and the expression change of PTEN, epithelial cadherin and vimentin. \u0000 \u0000 \u0000Results \u0000The relative expression levels of miR-106b in Hep-2 and TU212 cells in the experimental group were 0.110 ± 0.037 and 0.074 ± 0.009, respectively, which were lower than those in the negative control group (1.013±0.059 and 1.035±0.062, respectively; all P < 0.05). In Transwell experiments, the number of invasive cells in each field of Hep-2 and TU212 cells in the experimental group was less than that in the negative control group [(37.09±4.02) vs. (95.65±4.77), (29.16±2.49) vs. (103.19±6.08), all P < 0.05]. The bioinformatics analysis results showed that 3'-UTR region of PTEN mRNA was complementary to 3'-UTR region of miR-106b. Dual-luciferase reporter system analysis showed that the luciferase reporter activity of wild-type PTEN gene transfected with miR-106b was decreased to (22.84±2.68)%, and that of mutant PTEN gene transfected with miR-106b was almost unchanged [(92.08±3.44)%], and the difference was statistically significant (P < 0.001). The expression level of PTEN protein of Hep-2 and TU212 cells in the experimental group was higher than that in the negative control group. Transwell method showed that the number of invasive cells in each field of Hep-2 and TU212 cells in the experimental group with the inhibition of PTEN expression was more than that in the experimental group without the inhibition of PTEN expression [(65.08±3.57) vs. (26.72±2.58), (57.38±4.96) vs. (31.81±2.97), all P < 0.05]. Western blot showed that the expression level of epithelial-cadherin was up-regulated and vimentin was down-regulated of Hep-2 and TU212 cells in the experimental group with the inhibition of PTEN expression. \u0000 \u0000 \u0000Conclusions \u0000The human laryngeal squamous cell carcinoma Hep-2 and TU212 cell miR-106b can influence the downstream invasion-related protein of PTEN and change the cell invasion ability through the targeted regulation of PTEN expression. \u0000 \u0000 \u0000Key words: \u0000Laryngeal neoplasms; Carcinoma, s","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47527702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasonographic characteristics of hook wire-localized impalpable benign and malignant breast nodules and the diagnostic value analysis of ultrasonogragh and mammography 钩丝定位乳腺良恶性结节的超声特征及超声与钼靶x线诊断价值分析
Q4 Medicine Pub Date : 2020-02-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.010
R. Guo, Yuxiang Wang
目的 分析导丝定位后手术切除不能触及的乳腺良恶性病变的超声特征及超声与钼靶的诊断效能。 方法 选取山西省肿瘤医院2011年3月至2018年10月经超声引导下导丝定位后行手术切除的324例不能触及的乳腺结节患者,回顾性分析超声检查发现且不能触及的乳腺良恶性病变的超声及钼靶检查结果。 结果 58例恶性病变患者中浸润性导管癌33例,导管原位癌14例,小叶原位癌1例,浸润性小叶癌3例,浸润性导管癌合并导管内癌4例,黏液癌1例,髓样癌1例,浸润性导管癌合并浸润性小叶癌及导管原位癌1例。266例良性病变患者中纤维瘤167例,乳腺腺病61例,乳管内乳头状瘤31例,导管扩张5例,炎症性病变2例。边缘不完整、伴钙化这两个超声特征在判断不可触及的乳腺结节的良恶性中差异均有统计学意义(χ2=129.155,P<0.001;χ2=11.834,P=0.001)。以4B为良恶性的界值,超声的诊断灵敏度84.5%,特异度91.0%,阳性预测值67.1%;钼靶的诊断灵敏度77.6%,特异度93.2%,阳性预测值71.4%。钼靶和超声联合使用灵敏度93.1%,特异度86.8%,阳性预测值60.7%。 结论 不能触及的乳腺结节较难诊断,超声检查有助于鉴别诊断。超声诊断对不能触及的乳腺病变的灵敏度较高,钼靶的特异度较高,钼靶和超声联合使用能提高诊断灵敏度。
Objective: To analyze the ultrasound characteristics and diagnostic efficacy of ultrasound and molybdenum target in the removal of untouchable benign and malignant breast lesions after guided wire positioning surgery. Method: A retrospective analysis was conducted on 324 patients with untouchable breast nodules who underwent surgical resection under the guidance of ultrasound guided guide wire from March 2011 to October 2018 at Shanxi Provincial Cancer Hospital. The results of ultrasound and molybdenum target examinations were retrospectively analyzed for benign and malignant breast lesions that were found to be untouchable by ultrasound examination. Among the 58 patients with malignant lesions, there were 33 cases of invasive ductal carcinoma, 14 cases of ductal carcinoma in situ, 1 case of lobular carcinoma in situ, 3 cases of invasive lobular carcinoma, 4 cases of invasive ductal carcinoma combined with ductal carcinoma, 1 case of mucinous carcinoma, 1 case of medullary carcinoma, and 1 case of invasive ductal carcinoma combined with invasive lobular carcinoma and ductal carcinoma in situ. Among 266 patients with benign lesions, 167 were fibromas, 61 were breast adenomas, 31 were intraductal papillomas, 5 were ductal dilation, and 2 were inflammatory lesions. The difference between the two ultrasound features of incomplete margin and calcification in determining the benign and malignant status of untouchable breast nodules is statistically significant( χ 2=129.155, P<0.001; χ 2=11.834, P=0.001). Taking 4B as the boundary value for benign and malignant tumors, the diagnostic sensitivity of ultrasound is 84.5%, the specificity is 91.0%, and the positive predictive value is 67.1%; The diagnostic sensitivity of molybdenum target is 77.6%, specificity is 93.2%, and positive predictive value is 71.4%. The combination of molybdenum target and ultrasound has a sensitivity of 93.1%, a specificity of 86.8%, and a positive predictive value of 60.7%. Conclusion: Non palpable breast nodules are difficult to diagnose, and ultrasound examination is helpful in differential diagnosis. Ultrasound diagnosis has a high sensitivity for breast lesions that cannot be touched, and the specificity of molybdenum targets is high. The combination of molybdenum targets and ultrasound can improve diagnostic sensitivity.
{"title":"Ultrasonographic characteristics of hook wire-localized impalpable benign and malignant breast nodules and the diagnostic value analysis of ultrasonogragh and mammography","authors":"R. Guo, Yuxiang Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.010","url":null,"abstract":"目的 \u0000分析导丝定位后手术切除不能触及的乳腺良恶性病变的超声特征及超声与钼靶的诊断效能。 \u0000 \u0000 \u0000方法 \u0000选取山西省肿瘤医院2011年3月至2018年10月经超声引导下导丝定位后行手术切除的324例不能触及的乳腺结节患者,回顾性分析超声检查发现且不能触及的乳腺良恶性病变的超声及钼靶检查结果。 \u0000 \u0000 \u0000结果 \u000058例恶性病变患者中浸润性导管癌33例,导管原位癌14例,小叶原位癌1例,浸润性小叶癌3例,浸润性导管癌合并导管内癌4例,黏液癌1例,髓样癌1例,浸润性导管癌合并浸润性小叶癌及导管原位癌1例。266例良性病变患者中纤维瘤167例,乳腺腺病61例,乳管内乳头状瘤31例,导管扩张5例,炎症性病变2例。边缘不完整、伴钙化这两个超声特征在判断不可触及的乳腺结节的良恶性中差异均有统计学意义(χ2=129.155,P<0.001;χ2=11.834,P=0.001)。以4B为良恶性的界值,超声的诊断灵敏度84.5%,特异度91.0%,阳性预测值67.1%;钼靶的诊断灵敏度77.6%,特异度93.2%,阳性预测值71.4%。钼靶和超声联合使用灵敏度93.1%,特异度86.8%,阳性预测值60.7%。 \u0000 \u0000 \u0000结论 \u0000不能触及的乳腺结节较难诊断,超声检查有助于鉴别诊断。超声诊断对不能触及的乳腺病变的灵敏度较高,钼靶的特异度较高,钼靶和超声联合使用能提高诊断灵敏度。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49481864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of actin related protein 2/3 complex subunit 2 gene silencing on the proliferation and apoptosis of papillary thyroid carcinoma TPC-1 cells 肌动蛋白相关蛋白2/3复合体亚基2基因沉默对甲状腺乳头状癌TPC-1细胞增殖和凋亡的影响
Q4 Medicine Pub Date : 2020-02-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.02.001
Yizhou Bai, Anyang Liu, Wu Ji, B. Luo, Jin-Yi Tian
Objective To investigate the effect of actin related protein 2/3 complex subunit 2 (ARPC2) gene silencing on the biological characteristics of papillary thyroid carcinoma (PTC) TPC-1 cells through lentivirus-mediated RNA interference. Methods TPC-1 cells infected with nonsense short hairpin RNA (shRNA) sequence lentivirus (shCtrl) was used as the control group. TPC-1 cells infected with ARPC2 shRNA interference sequence lentivirus (shARPC2) was used as the experimental group, in which the expression of ARPC2 gene was specifically interfered. The effects of silencing the expression of ARPC2 gene on the proliferation of TPC-1 cells were detected by using methyl thiazolyl tetrazolium (MTT) assay, flow cytometry, Western blot and colony formation test. Flow cytometry and Western blot were conducted to detect the effect of silencing ARPC2 gene on TPC-1 cells apoptosis and related proteins. Results shARPC2 could efficiently infect TPC-1 cells, and the expression efficiency of green fluorescent protein was over 85%. Compared with the control group, TPC-1 proliferation was inhibited in the experimental group. The ratio of S-phase cells in the experimental group was reduced compared with that in the control group [(14.79±0.21)% vs. (21.13±0.33)%, t = 27.77, P < 0.05]. The ratio of G1 and G2/M-phase cells in the experimental group was increased compared with that in the control group [G1 phase: (67.57±0.08)% vs. (62.06±0.36)%, t=25.56, P < 0.05; G2/M phase: (17.64±0.12)% vs. (16.91±0.17)%, t=6.154, P < 0.05]. Meanwhile, the expressions of cell cycle-related proteins CDK2, CyclinE and CyclinD were reduced in the experimental group. The number of clone formation in the experimental group was less than that in the control group, the difference was statistically significant [(10±2) vs. (161±6), t=9.011, P < 0.05]. In addition, the apoptotic ratio of cells in the experimental group was higher than that in the control group [(8.60±0.77)% vs. (4.08±0.40)%, t=9.011, P < 0.05]. Western blot showed that the expressions of anti-apoptotic factors p21 and bcl-2 were reduced in the experimental group, while the expression of pro-apoptotic factor bax was increased. Conclusion The interference with the expression of ARPC2 regulated by shRNA can inhibit the proliferation, and promote the apoptosis of PTC TPC-1 cells, indicating that ARPC2 may be a possible biological new target for the treatment of PTC. Key words: Thyroid neoplasms; RNA interference; Cell proliferation; Apoptosis
目的通过慢病毒介导的RNA干扰研究肌动蛋白相关蛋白2/3复合亚基2(ARPC2)基因沉默对甲状腺乳头状癌(PTC)TPC-1细胞生物学特性的影响。方法用无义短发夹RNA(shRNA)序列慢病毒(shCtrl)感染TPC-1细胞作为对照组。以ARPC2 shRNA干扰序列慢病毒(shARPC2)感染的TPC-1细胞为实验组,对ARPC2基因的表达进行特异性干扰。采用MTT法、流式细胞仪、Western blot和集落形成试验等方法检测了ARPC2基因沉默对TPC-1细胞增殖的影响。采用流式细胞术和Western印迹法检测ARPC2基因沉默对TPC-1细胞凋亡及相关蛋白的影响。结果shARPC2能有效感染TPC-1细胞,绿色荧光蛋白的表达效率可达85%以上。与对照组相比,实验组TPC-1的增殖受到抑制。实验组S期细胞比例较对照组降低[(14.79±0.21)%vs.(21.13±0.33)%,t=27.77,P<0.05]。实验组G1期和G2/M期细胞比例与对照组相比增加[G1期:(67.57±0.08)%vs%同时,实验组细胞周期相关蛋白CDK2、CyclinE和CyclinD的表达降低。实验组克隆形成数少于对照组,差异有统计学意义[(10±2)vs.(161±6),t=9.011,P<0.05],实验组细胞凋亡率高于对照组[(8.60±0.77)%vs.(4.08±0.40)%,t=9.011,P<0.05]。结论干扰shRNA调控的ARPC2表达可抑制PTC TPC-1细胞的增殖,促进细胞凋亡,表明ARPC2可能是治疗PTC的一个新的生物学靶点。关键词:甲状腺肿瘤;RNA干扰;细胞增殖;细胞凋亡
{"title":"Effect of actin related protein 2/3 complex subunit 2 gene silencing on the proliferation and apoptosis of papillary thyroid carcinoma TPC-1 cells","authors":"Yizhou Bai, Anyang Liu, Wu Ji, B. Luo, Jin-Yi Tian","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.02.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.02.001","url":null,"abstract":"Objective \u0000To investigate the effect of actin related protein 2/3 complex subunit 2 (ARPC2) gene silencing on the biological characteristics of papillary thyroid carcinoma (PTC) TPC-1 cells through lentivirus-mediated RNA interference. \u0000 \u0000 \u0000Methods \u0000TPC-1 cells infected with nonsense short hairpin RNA (shRNA) sequence lentivirus (shCtrl) was used as the control group. TPC-1 cells infected with ARPC2 shRNA interference sequence lentivirus (shARPC2) was used as the experimental group, in which the expression of ARPC2 gene was specifically interfered. The effects of silencing the expression of ARPC2 gene on the proliferation of TPC-1 cells were detected by using methyl thiazolyl tetrazolium (MTT) assay, flow cytometry, Western blot and colony formation test. Flow cytometry and Western blot were conducted to detect the effect of silencing ARPC2 gene on TPC-1 cells apoptosis and related proteins. \u0000 \u0000 \u0000Results \u0000shARPC2 could efficiently infect TPC-1 cells, and the expression efficiency of green fluorescent protein was over 85%. Compared with the control group, TPC-1 proliferation was inhibited in the experimental group. The ratio of S-phase cells in the experimental group was reduced compared with that in the control group [(14.79±0.21)% vs. (21.13±0.33)%, t = 27.77, P < 0.05]. The ratio of G1 and G2/M-phase cells in the experimental group was increased compared with that in the control group [G1 phase: (67.57±0.08)% vs. (62.06±0.36)%, t=25.56, P < 0.05; G2/M phase: (17.64±0.12)% vs. (16.91±0.17)%, t=6.154, P < 0.05]. Meanwhile, the expressions of cell cycle-related proteins CDK2, CyclinE and CyclinD were reduced in the experimental group. The number of clone formation in the experimental group was less than that in the control group, the difference was statistically significant [(10±2) vs. (161±6), t=9.011, P < 0.05]. In addition, the apoptotic ratio of cells in the experimental group was higher than that in the control group [(8.60±0.77)% vs. (4.08±0.40)%, t=9.011, P < 0.05]. Western blot showed that the expressions of anti-apoptotic factors p21 and bcl-2 were reduced in the experimental group, while the expression of pro-apoptotic factor bax was increased. \u0000 \u0000 \u0000Conclusion \u0000The interference with the expression of ARPC2 regulated by shRNA can inhibit the proliferation, and promote the apoptosis of PTC TPC-1 cells, indicating that ARPC2 may be a possible biological new target for the treatment of PTC. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; RNA interference; Cell proliferation; Apoptosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45140494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expressions of coordinated stimulating molecular programmed death 1 and its ligand 1 in brain glioma and their clinical significances 协同刺激分子程序性死亡1及其配体1在脑胶质瘤中的表达及其临床意义
Q4 Medicine Pub Date : 2020-01-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.01.007
Jianhong Li, Lili Ma, Lina Zhang
Objective To analyze the expressions of coordinated stimulating molecular programmed death 1(PD-1) and programmed death ligand 1 (PD-L1) in human glioma and their clinical significances. Methods A total of 70 postoperative paraffin specimens of brain glioma and 35 normal brain tissues in Heji Hospital Affiliated to Changzhi Medical College from January 2013 to December 2017 were collected. The expressions of PD-1 and PD-L1 in 70 glioma tissues and 35 normal brain tissues were detected by immunohistochemical SP method. The relationship between the expressions of PD-1 and PD-L1 and their correlation with the clinicopathological features were analyzed. Results The positive expression rates of PD-1 and PD-L1 in glioma tissues were 69% (48/70) and 62% (43/70), respectively, which were higher than those in normal brain tissues [29% (10/35), 31% (11/35)], the differences were statistically significant (χ2 values were 15.099 and 8.407, both P 0.05). There was a positive correlation between the expressions of PD-1 and PD-L1 proteins in glioma tissues (r= 0.372, P= 0.002). Conclusions The PD-1 and PD-L1 may become new biological indicators for evaluating the occurrence and development of glioma. Key words: Brain neoplasms; Glioma; Programmed death 1; Programmed death ligand 1; Immunohistochemistry
目的分析协同刺激分子程序性死亡1(PD-1)和程序性死亡配体1(PD-L1)在人脑胶质瘤中的表达及其临床意义。方法收集长治医学院附属何济医院2013年1月至2017年12月的70例脑胶质瘤术后石蜡标本和35例正常脑组织标本。用免疫组化SP法检测了70例胶质瘤组织和35例正常脑组织中PD-1和PD-L1的表达。分析PD-1和PD-L1的表达与临床病理特征的关系。结果PD-1和PD-L1在胶质瘤组织中的阳性表达率分别为69%(48/70)和62%(43/70),高于正常脑组织[29%(10/35)、31%(11/35)],两者差异有统计学意义(χ2分别为15.099和8.407,均P<0.05)。胶质瘤组织中PD-1和PD-L1蛋白的表达呈正相关(r=0.372,P=0.002)。关键词:脑肿瘤;胶质瘤;程序性死亡1;程序性死亡配体1;免疫组织化学
{"title":"Expressions of coordinated stimulating molecular programmed death 1 and its ligand 1 in brain glioma and their clinical significances","authors":"Jianhong Li, Lili Ma, Lina Zhang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.007","url":null,"abstract":"Objective \u0000To analyze the expressions of coordinated stimulating molecular programmed death 1(PD-1) and programmed death ligand 1 (PD-L1) in human glioma and their clinical significances. \u0000 \u0000 \u0000Methods \u0000A total of 70 postoperative paraffin specimens of brain glioma and 35 normal brain tissues in Heji Hospital Affiliated to Changzhi Medical College from January 2013 to December 2017 were collected. The expressions of PD-1 and PD-L1 in 70 glioma tissues and 35 normal brain tissues were detected by immunohistochemical SP method. The relationship between the expressions of PD-1 and PD-L1 and their correlation with the clinicopathological features were analyzed. \u0000 \u0000 \u0000Results \u0000The positive expression rates of PD-1 and PD-L1 in glioma tissues were 69% (48/70) and 62% (43/70), respectively, which were higher than those in normal brain tissues [29% (10/35), 31% (11/35)], the differences were statistically significant (χ2 values were 15.099 and 8.407, both P 0.05). There was a positive correlation between the expressions of PD-1 and PD-L1 proteins in glioma tissues (r= 0.372, P= 0.002). \u0000 \u0000 \u0000Conclusions \u0000The PD-1 and PD-L1 may become new biological indicators for evaluating the occurrence and development of glioma. \u0000 \u0000 \u0000Key words: \u0000Brain neoplasms; Glioma; Programmed death 1; Programmed death ligand 1; Immunohistochemistry","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43237711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress of signaling pathways related to bone destruction after bone metastasis in prostate cancer 前列腺癌骨转移后骨破坏相关信号通路的研究进展
Q4 Medicine Pub Date : 2020-01-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.01.014
Zhengqin Geng, Ling Zhou, Jiadai Tang
Bone metastasis is one of the common complications of patients with advanced prostate cancer. The treatment of skeletal-related events (SRE) caused by bone metastasis, such as the pain, is not effective, and the prognosis is poor, which seriously affects the quality of life of patients. Therefore, exploring the bone metastasis of prostate cancer is of great significance. At present, the relevant mechanism of bone metastasis is still unclear, and the vicious cycle formed by the interaction between the host microenvironment and prostate cancer cells, might be an important reason, among which, the research on RANK-RANKL signaling pathway is relatively mature. This article reviews the current research status of prostate cancer bone metastasis-related signaling pathways, and describes the regulatory relationships of the same signaling molecules in different signaling pathways. Key words: Prostate neoplasms; Bone metastasis; Signaling pathway
骨转移是晚期前列腺癌患者常见的并发症之一。骨转移引起的骨相关事件(SRE)如疼痛等治疗效果不佳,预后差,严重影响患者的生活质量。因此,探讨前列腺癌的骨转移具有重要意义。目前骨转移的相关机制尚不清楚,宿主微环境与前列腺癌细胞相互作用形成的恶性循环可能是重要原因,其中RANK-RANKL信号通路的研究相对成熟。本文综述了前列腺癌骨转移相关信号通路的研究现状,并阐述了相同信号分子在不同信号通路中的调控关系。关键词:前列腺肿瘤;骨转移;信号通路
{"title":"Progress of signaling pathways related to bone destruction after bone metastasis in prostate cancer","authors":"Zhengqin Geng, Ling Zhou, Jiadai Tang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.014","url":null,"abstract":"Bone metastasis is one of the common complications of patients with advanced prostate cancer. The treatment of skeletal-related events (SRE) caused by bone metastasis, such as the pain, is not effective, and the prognosis is poor, which seriously affects the quality of life of patients. Therefore, exploring the bone metastasis of prostate cancer is of great significance. At present, the relevant mechanism of bone metastasis is still unclear, and the vicious cycle formed by the interaction between the host microenvironment and prostate cancer cells, might be an important reason, among which, the research on RANK-RANKL signaling pathway is relatively mature. This article reviews the current research status of prostate cancer bone metastasis-related signaling pathways, and describes the regulatory relationships of the same signaling molecules in different signaling pathways. \u0000 \u0000 \u0000Key words: \u0000Prostate neoplasms; Bone metastasis; Signaling pathway","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47288761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress of Wnt-β-catenin signaling pathway related long non-coding RNA in glioma 神经胶质瘤中Wnt-β-catenin信号通路相关长非编码RNA的研究进展
Q4 Medicine Pub Date : 2020-01-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.01.013
X. Ren, Hu-Bin Duan, Youchao Xiao, J. Hao
Glioma is one of the most common and invasive malignant tumors in the central nervous system. The Wnt-β-catenin signaling pathway is a classical Wnt pathway, which is involved in the occurrence and development of glioma and other tumors. Long non-coding RNA (LncRNA) is a functional RNA molecule without protein coding function, which plays a regulatory role in the occurrence and development of various tumors. Recent studies have shown that LncRNA and Wnt-β-catenin signaling pathways are jointly involved in glioma growth, invasion, migration and other processes, but the complex mechanism has not been thoroughly elaborated. In this paper, the influence of Wnt-β-catenin signaling pathway and its related LncRNA on glioma was reviewed, and the pathogenesis of glioma was deeply understood, so as to find a better way for the diagnosis and treatment of glioma. Key words: Glioma; Wnt signaling pathway; Wnt-β-catenin signaling pathway; Long non-coding RNA
胶质瘤是中枢神经系统最常见的侵袭性恶性肿瘤之一。Wnt-β-catenin信号通路是典型的Wnt通路,参与胶质瘤等肿瘤的发生发展。长链非编码RNA (Long non-coding RNA, LncRNA)是一种不具有蛋白质编码功能的功能性RNA分子,在各种肿瘤的发生发展中发挥调控作用。近年来的研究表明,LncRNA和Wnt-β-catenin信号通路共同参与胶质瘤的生长、侵袭、迁移等过程,但其复杂机制尚未得到深入阐述。本文就Wnt-β-catenin信号通路及其相关LncRNA对胶质瘤的影响进行综述,深入了解胶质瘤的发病机制,以期为胶质瘤的诊断和治疗寻找更好的方法。关键词:胶质瘤;Wnt信号通路;Wnt-β-catenin信号通路;长链非编码RNA
{"title":"Progress of Wnt-β-catenin signaling pathway related long non-coding RNA in glioma","authors":"X. Ren, Hu-Bin Duan, Youchao Xiao, J. Hao","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.013","url":null,"abstract":"Glioma is one of the most common and invasive malignant tumors in the central nervous system. The Wnt-β-catenin signaling pathway is a classical Wnt pathway, which is involved in the occurrence and development of glioma and other tumors. Long non-coding RNA (LncRNA) is a functional RNA molecule without protein coding function, which plays a regulatory role in the occurrence and development of various tumors. Recent studies have shown that LncRNA and Wnt-β-catenin signaling pathways are jointly involved in glioma growth, invasion, migration and other processes, but the complex mechanism has not been thoroughly elaborated. In this paper, the influence of Wnt-β-catenin signaling pathway and its related LncRNA on glioma was reviewed, and the pathogenesis of glioma was deeply understood, so as to find a better way for the diagnosis and treatment of glioma. \u0000 \u0000 \u0000Key words: \u0000Glioma; Wnt signaling pathway; Wnt-β-catenin signaling pathway; Long non-coding RNA","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41622218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Diagnostic value of folate receptor-positive circulating tumor cell detection in subcentimeter pulmonary nodules 叶酸受体阳性循环肿瘤细胞检测对亚细胞肺结节的诊断价值
Q4 Medicine Pub Date : 2020-01-28 DOI: 10.3760/CMA.J.ISSN.1006-9801.2020.01.001
Gaojun Lu, Ruo-tian Wang, X. Tian, Xin Jin
Objective To investigate the value of the folate receptor (FR)-positive circulating tumor cell (CTC) detection in the diagnosis of benign and malignant subcentimeter pulmonary nodules(the maximum diameter ≤10 mm). Methods Thirty-seven patients with subcentimeter pulmonary nodules (the chest CT showed the maximum diameter was ≤10 mm) in the Xuanwu Hospital of Capital Medical University from July to December 2018 were collected. Among them, 22 cases were diagnosed with early stage lung adenocarcinoma by postoperative pathological diagnosis and another 15 cases were benign lung lesion. Venous blood samples from these patients were collected before surgery and then utilized to detect FR+ CTC level (defined unit as FU/3 ml) by novel ligand-targeted polymerase chain reaction (LT-PCR), and the enzyme-linked immunosorbent assay was used to detect the levels of tumor markers, including carcinoembryonic antigen (CEA), neuron-specific enolase(NSE), cytokeratin 19 fragment CYFRA21-1, carbohydrate antigen 125 (CA125), CA199, pro-gastrin releasing peptide (pro-GRP), etc. The t-test was used to compare the measurement values between the groups. The CTC value 8.70 FU/3 ml described in the detection kit instruction was used as the threshold. The binary logistic regression was used to analyze the risk factors of malignant pulmonary nodules. The kappa consistency test was used to identify the consistency of the diagnosis results obtained by the FR+ CTC level and the pathological results of surgically resected specimens. The receiver operating characteristic curve (ROC) was drawn to evaluate the efficiency of each index for the diagnosis of benign and malignant subcentimeter pulmonary nodules. Results The level of FR+ CTC in patients with early stage lung cancer was higher than that in patients with benign lung lesion, and the difference was statistically significant [(11.0±3.0) FU/3 ml vs. (7.0±3.7) FU/3 ml, t=-3.327, P = 0.001]. The level of FR+ CTC was not related to the age, gender and smoking history of patients (all P>0.05). Logistic regression analysis indicated that high-level FR+ CTC was one of the risk factors for malignant pulmonary nodules (OR = 37.333, 95% CI 3.994-349.010, P = 0.002). The kappa consistency test indicated that the level of FR+ CTC used for the diagnosis of lung subcentimeter nodules presented a certain accuracy (κ = 0.627, P < 0.01). ROC illustrated that the FR+ CTC was better than CEA, NSE and CYFRA21-1 when it was used as an indicator for the diagnosis of malignant pulmonary nodules. The area under the curve(AUC) of FR+ CTC was 0.830 (95% CI 0.639-0.968), and the diagnostic sensitivity and specificity were 72.7% (95% CI 49.6%-88.4%) and 93.3% (95% CI 66.0%-99.7%), respectively. When FR+ CTC, CEA, NSE and CYFRA21-1 were combined for lung cancer diagnosis, the AUC, sensitivity and specificity were 0.776 (95% CI 0.614-0.938), 86.4% and 73.3%, respectively. Conclusion The detection of FR+ CTC has a high value in the dia
目的探讨叶酸受体(FR)阳性循环肿瘤细胞(CTC)检测在肺部良恶性(最大直径≤10mm)结节诊断中的价值。方法收集首都医科大学宣武医院2018年7月至12月收治的37例肺结节(胸部CT显示最大直径≤10mm)患者。其中22例经术后病理诊断为早期肺腺癌,15例为肺部良性病变。术前采集这些患者的静脉血样,然后通过新型配体靶向聚合酶链式反应(LT-PCR)检测FR+CTC水平(定义单位为FU/3ml),并使用酶联免疫吸附法检测肿瘤标志物的水平,包括癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段CYFRA21-1,碳水化合物抗原125(CA125)、CA199、促胃泌素释放肽(pro-GRP)等。使用t检验比较各组之间的测量值。检测试剂盒说明书中描述的CTC值8.70 FU/3ml用作阈值。采用二元逻辑回归分析肺部恶性结节的危险因素。κ一致性检验用于确定通过FR+CTC水平获得的诊断结果与手术切除标本的病理结果的一致性。绘制受试者工作特征曲线(ROC),以评估各指标对良恶性亚单位肺结节诊断的有效性。结果早期癌症患者FR+CTC水平高于良性肺病变患者,差异有统计学意义[(11.0±3.0)FU/3ml与(7.0±3.7)FU/3/ml,t=-3.327,P=0.001],Logistic回归分析表明,高水平FR+CTC是肺恶性结节的危险因素之一(OR=37.333,95%CI 3.994-349.010,P=0.002)。κ说明FR+CTC在用作诊断恶性肺结节的指标时优于CEA、NSE和CYFRA21-1。FR+CTC的曲线下面积(AUC)为0.830(95%CI0.639-0.968),诊断灵敏度和特异性分别为72.7%(95%CI49.6%-88.4%)和93.3%(95%CI66.0%-99.7%)。联合应用FR+CTC、CEA、NSE和CYFRA21-1诊断癌症,AUC、敏感性和特异性分别为0.776(95%CI 0.614-0.938)、86.4%和73.3%。结论FR+CTC检测对肺部良恶性亚单位结节的诊断具有较高价值。关键词:叶酸受体;新生细胞,循环;肺结节;肺肿瘤;亚厘米结节
{"title":"Diagnostic value of folate receptor-positive circulating tumor cell detection in subcentimeter pulmonary nodules","authors":"Gaojun Lu, Ruo-tian Wang, X. Tian, Xin Jin","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.001","url":null,"abstract":"Objective \u0000To investigate the value of the folate receptor (FR)-positive circulating tumor cell (CTC) detection in the diagnosis of benign and malignant subcentimeter pulmonary nodules(the maximum diameter ≤10 mm). \u0000 \u0000 \u0000Methods \u0000Thirty-seven patients with subcentimeter pulmonary nodules (the chest CT showed the maximum diameter was ≤10 mm) in the Xuanwu Hospital of Capital Medical University from July to December 2018 were collected. Among them, 22 cases were diagnosed with early stage lung adenocarcinoma by postoperative pathological diagnosis and another 15 cases were benign lung lesion. Venous blood samples from these patients were collected before surgery and then utilized to detect FR+ CTC level (defined unit as FU/3 ml) by novel ligand-targeted polymerase chain reaction (LT-PCR), and the enzyme-linked immunosorbent assay was used to detect the levels of tumor markers, including carcinoembryonic antigen (CEA), neuron-specific enolase(NSE), cytokeratin 19 fragment CYFRA21-1, carbohydrate antigen 125 (CA125), CA199, pro-gastrin releasing peptide (pro-GRP), etc. The t-test was used to compare the measurement values between the groups. The CTC value 8.70 FU/3 ml described in the detection kit instruction was used as the threshold. The binary logistic regression was used to analyze the risk factors of malignant pulmonary nodules. The kappa consistency test was used to identify the consistency of the diagnosis results obtained by the FR+ CTC level and the pathological results of surgically resected specimens. The receiver operating characteristic curve (ROC) was drawn to evaluate the efficiency of each index for the diagnosis of benign and malignant subcentimeter pulmonary nodules. \u0000 \u0000 \u0000Results \u0000The level of FR+ CTC in patients with early stage lung cancer was higher than that in patients with benign lung lesion, and the difference was statistically significant [(11.0±3.0) FU/3 ml vs. (7.0±3.7) FU/3 ml, t=-3.327, P = 0.001]. The level of FR+ CTC was not related to the age, gender and smoking history of patients (all P>0.05). Logistic regression analysis indicated that high-level FR+ CTC was one of the risk factors for malignant pulmonary nodules (OR = 37.333, 95% CI 3.994-349.010, P = 0.002). The kappa consistency test indicated that the level of FR+ CTC used for the diagnosis of lung subcentimeter nodules presented a certain accuracy (κ = 0.627, P < 0.01). ROC illustrated that the FR+ CTC was better than CEA, NSE and CYFRA21-1 when it was used as an indicator for the diagnosis of malignant pulmonary nodules. The area under the curve(AUC) of FR+ CTC was 0.830 (95% CI 0.639-0.968), and the diagnostic sensitivity and specificity were 72.7% (95% CI 49.6%-88.4%) and 93.3% (95% CI 66.0%-99.7%), respectively. When FR+ CTC, CEA, NSE and CYFRA21-1 were combined for lung cancer diagnosis, the AUC, sensitivity and specificity were 0.776 (95% CI 0.614-0.938), 86.4% and 73.3%, respectively. \u0000 \u0000 \u0000Conclusion \u0000The detection of FR+ CTC has a high value in the dia","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43811463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
肿瘤研究与临床
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1